Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:MRKR OTCMKTS:PFSCF NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$15.55+6.6%$15.52$3.38▼$26.95$1.23B0.941.34 million shs980,529 shsMRKRMarker Therapeutics$1.46+1.4%$1.44$0.81▼$4.07$24.01M1.4390,863 shs41,793 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AXERSXeris Biopharma$6.53-1.5%$5.92$4.30▼$10.08$1.14B0.851.51 million shs3.02 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-3.95%-1.95%-28.69%+355.23%MRKRMarker Therapeutics0.00%-1.37%-1.37%-12.73%+29.73%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma0.00%+8.16%+11.99%-5.42%+48.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$15.55+6.6%$15.52$3.38▼$26.95$1.23B0.941.34 million shs980,529 shsMRKRMarker Therapeutics$1.46+1.4%$1.44$0.81▼$4.07$24.01M1.4390,863 shs41,793 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AXERSXeris Biopharma$6.53-1.5%$5.92$4.30▼$10.08$1.14B0.851.51 million shs3.02 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-3.95%-1.95%-28.69%+355.23%MRKRMarker Therapeutics0.00%-1.37%-1.37%-12.73%+29.73%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma0.00%+8.16%+11.99%-5.42%+48.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.75Moderate Buy$33.33114.36% UpsideMRKRMarker Therapeutics 2.25Hold$10.00584.93% UpsidePFSCFProMetic Life Sciences 0.00N/AN/AN/AXERSXeris Biopharma 2.57Moderate Buy$10.8065.39% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, XERS, PFSCF, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.003/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026CRVSCorvus Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight3/13/2026CRVSCorvus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $33.003/4/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Hold (C-)3/2/2026XERSXeris Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/A$0.14 per share115.10$0.73 per shareN/AMRKRMarker Therapeutics$3.55M6.86N/AN/A$1.01 per share1.45PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08XERSXeris Biopharma$291.85M3.86$0.10 per share66.19$0.08 per share81.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$15.28M-$0.50N/AN/AN/AN/A-62.15%-54.97%N/AMRKRMarker Therapeutics-$12.16M-$0.85N/AN/AN/A-343.03%-80.86%-67.04%5/21/2026 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/AN/AN/AN/A-894.02%-3,350.55%-67.76%N/AXERSXeris Biopharma$550K-$0.01108.8318.14N/A3.81%-556.27%3.31%N/ALatest CRVS, XERS, PFSCF, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026MRKRMarker Therapeutics-$0.18N/AN/AN/A$0.68 millionN/A5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 million3/12/2026Q4 2025CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A3/2/2026Q4 2025XERSXeris Biopharma$0.03$0.0615+$0.0315$0.06$86.00 million$85.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A6.216.21MRKRMarker TherapeuticsN/A8.398.39PFSCFProMetic Life SciencesN/A0.950.71XERSXeris Biopharma16.102.191.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%MRKRMarker Therapeutics22.39%PFSCFProMetic Life Sciences0.10%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals19.70%MRKRMarker Therapeutics5.70%PFSCFProMetic Life SciencesN/AXERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionableXERSXeris Biopharma290172.63 million161.46 millionOptionableCRVS, XERS, PFSCF, and MRKR HeadlinesRecent News About These CompaniesXeris Biopharma Q1 Earnings Call HighlightsMay 9 at 4:06 AM | marketbeat.comXeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedMay 8 at 1:35 PM | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Posts Earnings ResultsMay 7 at 10:49 PM | marketbeat.comXeris (XERS) Q1 2026 Earnings Call TranscriptMay 7 at 5:33 PM | aol.comAXeris Biopharma: Q1 Earnings SnapshotMay 7 at 5:33 PM | wtop.comWXeris Biopharma Reports First Quarter 2026 Financial ResultsMay 7 at 5:33 PM | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call TranscriptMay 7 at 2:03 PM | seekingalpha.comXeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 7 at 10:31 AM | zacks.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $103,835.41 in StockMay 4, 2026 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesMay 2, 2026 | insidertrades.comBeth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) StockMay 1, 2026 | marketbeat.comXeris Biopharma (XERS) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsApril 24, 2026 | marketbeat.comXeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay RevealedApril 23, 2026 | quiverquant.comQXeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comXeris Biopharma Announces Board Transition as Director RetiresApril 21, 2026 | tipranks.comXeris Biopharma Holdings, Inc. $XERS Shares Sold by Tudor Investment Corp ET ALApril 17, 2026 | marketbeat.comXeris Biopharma Holdings, Inc.April 16, 2026 | edition.cnn.comDoes Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)?April 13, 2026 | finance.yahoo.comXeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2026 | businesswire.comXeris Biopharma (NASDAQ:XERS) Director James Aloysius Brady Sells 10,834 SharesApril 3, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, XERS, PFSCF, and MRKR Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$15.55 +0.96 (+6.58%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$15.53 -0.02 (-0.13%) As of 05/8/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Marker Therapeutics NASDAQ:MRKR$1.46 +0.02 (+1.39%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 05/8/2026 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Xeris Biopharma NASDAQ:XERS$6.53 -0.10 (-1.51%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$6.54 +0.01 (+0.23%) As of 05/8/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
